BioNTech buys Biotheus and its Keytruda rival for $950m
1 day ago · BioNTech said that BNT327 has the "potential to replace current checkpoint inhibitor standard of care treatments for solid tumours." It is paying $800 million to acquire all of Biotheus' issued ...
Merck Provides Update on Phase 3 KEYLYNK-006 Trial Evaluating KEYTRUDA …
Mar 21, 2024 · KEYLYNK-006 is a randomized, open-label, two-phase Phase 3 trial (ClinicalTrials.gov, NCT03976323) evaluating KEYTRUDA in combination with chemotherapy (pemetrexed plus carboplatin or cisplatin...
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Combined …
May 5, 2021 · KEYTRUDA, in combination with chemotherapy, is indicated for the treatment of patients with locally recurrent unresectable or metastatic triple-negative breast cancer (TNBC) whose tumors express PD-L1 (CPS ≥10) as determined by an FDA-approved test.
Moderna, Merck cancer vaccine with Keytruda improved survival …
Jun 3, 2024 · The vaccine together with Merck’s Keytruda improved survival and showed long-lasting efficacy in a midstage study in patients with a deadly form of skin cancer. Moderna and Merck are presenting...
FDA approves pembrolizumab as adjuvant treatment for ...
On January 26, 2023, the Food and Drug Administration (FDA) approved pembrolizumab (Keytruda, Merck) for adjuvant treatment following resection and platinum-based chemotherapy for stage IB...
FDA Approves Merck's KEYTRUDA® (pembrolizumab)
Jun 17, 2024 · KEYTRUDA is now the first and only anti-PD-1 therapy FDA-approved in combination with chemotherapy for adult patients with primary advanced or recurrent endometrial carcinoma regardless of mismatch repair status. Approval marks the third FDA-approved indication for KEYTRUDA in endometrial carcinoma and …
Merck licenses Chinese cancer drug, trying to keep oncology lead
14 hours ago · Nov. 14, 2024. In a move to safeguard the company’s dominant position in cancer, Merck said Thursday it will license a new cancer drug from LaNova Medicines, a Shanghai-based firm, for $588 ...
FDA approves neoadjuvant/ adjuvant pembrolizumab for ...
On October 16, 2023, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) with platinum-containing chemotherapy as neoadjuvant treatment, and with continuation of...
FDA approves pembrolizumab with chemotherapy ...
On November 16, 2023, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) with fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of adults...
FDA Approves Merck's KEYTRUDA® (pembrolizumab)
Nov 16, 2023 · Approval based on results from the Phase 3 KEYNOTE-859 trial, which demonstrated significant improvement in overall survival in these patients versus chemotherapy alone. Approval marks seventh gastrointestinal cancer indication for KEYTRUDA-based regimens and 38th indication for KEYTRUDA in the US.